Saudi Arabia launches RFP for national dialysis services PPP project

By Zawya

By Staff Writer

Saudi Arabia's Ministry of Health (MOH) and National Centre for Privatisation & PPP (NCP) have launched the request for proposals (RFP) phase for the Chronic Kidney Disease Care & National Dialysis Services public-private partnership (PPP) project.

The RFP was launched on 19 October 2026, following the announcement of 12 prequalified bidders, comprising five consortia and seven individual companies, on 4 October.

The five prequalified consortia are 1) Saudi Arabia’s Care Medical and NephroTech 2) Saudi Arabia’s D.med Healthcare, SMC Hospitals and Al Saedan Real Estate; 3) Germany’s B. Braun and Saudi Arabia’s Gulf Medical Co.; 4) India’s NephroPlus and Saudi Arabia’s Al Faisaliah Healthcare Systems; and 5) China’s WEGO Medical and Saudi Arabia’s ANFAS.

The seven individually prequalified companies are Sweden’s Diaverum, Germany’s NephroCare, Saudi Arabia’s Almana, Saudi Arabia’s Dr. Sulaiman Al Habib Medical Group, US-based U.S. Renal Care, US-based DaVita and UAE-based Burjeel Holdings.

The project forms part of Saudi Arabia's healthcare privatisation and PPP programme.

The authorities did not disclose the RFP submission deadline.

(Writing by SA Kader; Editing by Anoop Menon)

(anoop.menon@lseg.com)

Subscribe to our Projects' PULSE newsletter that brings you trustworthy news, updates and insights on project activities, developments, and partnerships across sectors in the Middle East and Africa.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.